Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Rejects Apple Trade Secret Theft Claims 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
France Targets Shein, Temu With Fast-Fashion Fees 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
DALLAS and FORT WORTH, Texas, March 05, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics, will present a company overview at the upcoming Cowen & Co. 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:30 p.m. ET in Boston, MA.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
CONTACTS:
Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
[email protected]
Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]
